*Receipt date: 06/06/2005

10/537647 1009 R PCT/PTO 0 6 JUN 2005

. 10537647 - GAU: 1636

ATTORNEY DOCKET No.: 08830-0344US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE ACTING AS THE DESIGNATED/ELECTED OFFICE

In re: Patent application of: Koen VANDENBROECK; Iraide ALLOZA

Application No.:

Not Yet Assigned

(International Application No. PCT/IB2003/006404)

Filed:

Herewith

(International Application: 8 December 2003 (08.12.2003))

For:

RECOMBINANT CELL LINE

INFORMATION DISCLOSURE STATEMENT

MAIL STOP PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The present application is a 371 of PCT/IB2003/006404. Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §\$1.97-1.98, submitted herewith in duplicate is a substitute PTO Form 1449 listing the references cited in the Search Report in the international phase. It is believed that copies of the references have been or will be forwarded by the International Search Authority. Examiner is encouraged to contact the undersigned if reference copies have not been received.

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.10

EXPRESS MAIL Mailing Label Number:

EV 320480627 US

Date of Deposit:

06 JUNE 2005

I hereby certify that this correspondence, along with any paper referred to as being attached or enclosed, and/or fee, is being deposited with the United States Postal Service, "EXPRESS MAIL-POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10, on the date indicated above, and addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Signature of person mailing page:

Leola P. Goodman

Type or print name of person

*Receipt date: 06/06/2005

10/537647 10537647-GAU: 1636 CO9 RePPCT/PTO 0 6 JUN 2005,

The Examiner is respectfully requested to review the items listed on the PTO Form 1449 and make them of record in the instant application as required by M.P.E.P. §609. It is requested that the Examiner initial the enclosed duplicate substitute Form 1449, and return one copy to the undersigned.

This Information disclosure Statement should not be construed as a representation that the cited references are material or that more relevant prior art does not exist.

This statement is being submitted before receipt of any office action on the merits. Thus, no fee is due for the filing of this paper. However, if a fee is due, please charge deposit account 50-0573.

Respectfully submitted,

KOEN VANDENBROECK et al.

B

DANIEL A. MONACO Registration No. 30,480

DRINKER BIDDLE & REATH LLP

One Logan Square

18th and Cherry Streets

Philadelphia, PA 19103-6996

TEL: (215) 988-3312

FAX: (215) 988-2757 Attorney for Applicants *Receipt date: 06/06/2005



Sheet 1 of 1

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 08830-0344US1	SERIAL NO. Not Yet Known
INFORMATION DISC	CLOSURE STATEMENT		International No.: PCT/IB2003/006404
		APPLICANT:	
		Koen Vandenbroeck et al.	
		FILING DATE	GROUP 1636
		Herewith	Not Yet Known

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
7C.H./	AA	5,972,986	10/26/1999	Seibert et al.	514	406	
7C.H./	AB	2002/0119193	8/29/2002	Le et al.	424	465	

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA YES	ATION NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/C.H./	AC	Dunlop et al., "Inducible Expression And Pharmacology Of The Human Excitatory Amino Acid Transporter 2
, 3		Subtype Of L-Glutamate Transporter", British Journal Of Pharmacology 128:1485-1490 (1999)
/C.H./	AD	Graham et al., "Ecdysone-Controlled Expression Of Transgenes", Expert Opinion On Biological Therapy 2:525-
/ 03 13/		535 (2002)
/C.H./	AE	Martens et al., "Protein Disulfide Isomerase-Mediated Cell-Free Assembly Of Recombinant Interleukin-12 p40
70.11.7		Homodimers", European Journal Of Biochemistry 267:6679-6683 (2000)
/C.H./	AF	Nagy et al., "Inducible Expression And Pharmacology Of Recombinant NMDA Receptors, Composed Of Rat
, 011.11		NR1a/NR2B Subunits", Neurochemistry International 43:19-29 (2003)
/C.H./	AG	Davies et al., "Clinical Pharmacokinetics And Pharmacodynamics Of Celecoxib", Clinical Pharmacokinetics
		38:225-242 (2000)
/C.H./	AH	Chen et al., "Selective Inhibition Of COX-2 Is Beneficial To Mice Infected Intranasally With VSV"
, (31, 11)		Prostaglandins And Other Lipid Mediators 67:143-155 (2002)
/C.H./	AI	Cuzzocrea et al., "Celecoxib, A Selective Cyclo-Oxygenase-2 Inhibitor Reduces The Severity Of Experimental
/О.П./		Colitis Induced By Dinitrobenze Sulfonic Acid In Rats", European Journal Pharmacology 431:91-102 (2001)

EXAMINER /Catherine Hibbert/ DATE CONSIDERED 05/22/2009

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

·Receipt date: 06/06/2005

JC09 Rec'a CT/PTO 0 6 JUN 2005

Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE ATTY. DOCKET NO. SERIAL NO. PATENT AND TRADEMARK OFFICE 08830-0344US1 Not Yet Known **International No.:** PCT/IB2003/006404 INFORMATION DISCLOSURE STATEMENT APPLICANT: Koen Vandenbroeck et al. FILING DATE GROUP 1636 Herewith Not Yet Known

ILS. PATENT DOCUMENTS

C.S. IMILALI BOCCHILLUS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
/C.H./	AA	5,972,986	10/26/1999	Seibert et al.	514	406	
/C.H./	AB	2002/0119193	8/29/2002	Le et al.	424	465	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA YES	ATION NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/C.H./	AC	Dunlop et al., "Inducible Expression And Pharmacology Of The Human Excitatory Amino Acid Transporter 2
		Subtype Of L-Glutamate Transporter", British Journal Of Pharmacology 128:1485-1490 (1999)
/C.H./	AD	Graham et al., "Ecdysone-Controlled Expression Of Transgenes", Expert Opinion On Biological Therapy 2:525-
/0.11./		535 (2002)
/C.H./	AE	Martens et al., "Protein Disulfide Isomerase-Mediated Cell-Free Assembly Of Recombinant Interleukin-12 p40
/ 0.1 1.7		Homodimers", European Journal Of Biochemistry 267:6679-6683 (2000)
10.11.1	AF	Nagy et al., "Inducible Expression And Pharmacology Of Recombinant NMDA Receptors, Composed Of Rat
/C.H./		NR1a/NR2B Subunits", Neurochemistry International 43:19-29 (2003)
10.11	AG	Davies et al., "Clinical Pharmacokinetics And Pharmacodynamics Of Celecoxib", Clinical Pharmacokinetics
/C.H./		38:225-242 (2000)
/C.H./	AH	Chen et al., "Selective Inhibition Of COX-2 Is Beneficial To Mice Infected Intranasally With VSV"
/U.n./	:	Prostaglandins And Other Lipid Mediators 67:143-155 (2002)
10.11.1	ΑI	Cuzzocrea et al., "Celecoxib, A Selective Cyclo-Oxygenase-2 Inhibitor Reduces The Severity Of Experimental
/C.H./		Colitis Induced By Dinitrobenze Sulfonic Acid In Rats", European Journal Pharmacology 431:91-102 (2001)

EXAMINER	/Catherine Hibbert/	DATE CONSIDERED 05/22/2009
	•	ation is in conformance with MPEP 609; Draw line through citation form with next communication to applicant.